Glutamate as a spectroscopic marker of hippocampal structural plasticity is elevated in long-term euthymic bipolar patients on chronic lithium therapy and correlates inversely with diurnal cortisol.
While an excess of glucocorticoids is associated with hippocampal pathology in mood disorders, lithium exerts robust neuroprotective and neurotrophic effects. Here, 21 stably remitted bipolar I patients who had been on chronic lithium maintenance therapy, on average, for more than a decade, and 19 carefully matched healthy controls were studied using 3 T (1)H-magnetic resonance spectroscopy of left and right hippocampus. Salivary cortisol samples were obtained to assess activity of the hypothalamus-pituitary-adrenal system. Absolute concentrations of N-acetylaspartate (NAA), choline-containing compounds and total creatine were similar in euthymic bipolar patients and healthy controls. Hippocampal glutamate concentrations were significantly increased as an effect of patient status (patients>controls) and laterality (left hippocampus>right hippocampus). Hippocampal glutamate content (Glu) was strongly correlated with NAA. Across groups and within the patient group, diurnal saliva cortisol levels showed a significant inverse relationship with both Glu and NAA. Taken together, these results add to the concept of bipolar disorder as an illness involving disturbed hippocampal structural plasticity under the opposing influences of lithium and glucocorticoids.
Colla
M
M
Department of Psychiatry, Charité, Campus Benjamin Franklin, Berlin, Germany. michael.colla@charite.de
Schubert
F
F
Bubner
M
M
Heidenreich
J O
JO
Bajbouj
M
M
Seifert
F
F
Luborzewski
A
A
Heuser
I
I
Kronenberg
G
G
D000328:Adult; D000368:Aged; D018692:Antimanic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D001714:Bipolar Disorder / Q000188:drug therapy / Q000473:pathology; D016022:Case-Control Studies; D002794:Choline / Q000378:metabolism; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology*; D003401:Creatine / Q000378:metabolism; D005260:Female; D018698:Glutamic Acid / Q000378:metabolism*; D006624:Hippocampus / Q000473:pathology*; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism*; D016014:Linear Models; D018021:Lithium Chloride / Q000494:pharmacology / Q000627:therapeutic use*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008297:Male; D008875:Middle Aged; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology*; D012463:Saliva / Q000378:metabolism
D018692:Antimanic Agents; D001224:Aspartic Acid; D018698:Glutamic Acid; C000179:N-acetylaspartate; D018021:Lithium Chloride; D003401:Creatine; D002794:Choline; D006854:Hydrocortisone